日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Indicators of Clinical Trajectory in Patients With Cancer Who Receive Cardiopulmonary Resuscitation

接受心肺复苏的癌症患者的临床轨迹指标

Chawla, Sanjay; Gutierrez, Cristina; Rajendram, Prabalini; Seier, Kenneth; Tan, Kay See; Stoudt, Kara; Von-Maszewski, Marian; Morales-Estrella, Jorge L; Kostelecky, Natalie T; Voigt, Louis P

Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications

细胞治疗相关毒性的管理和预防:早期和晚期并发症

Mucha, Simon R; Rajendram, Prabalini

Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study

接受嵌合抗原受体相关毒性治疗的危重患者:一项多中心研究

Gutierrez, Cristina; Brown, Anne Rain T; May, Heather P; Beitinjaneh, Amer; Stephens, R Scott; Rajendram, Prabalini; Nates, Joseph L; Pastores, Stephen M; Dharshan, Ananda; de Moraes, Alice Gallo; Hensley, Matthew K; Feng, Lei; Brudno, Jennifer N; Athale, Janhavi; Ghosh, Monalisa; Kochenderfer, James N; Arias, Alejandro S; Lin, Yi; McEvoy, Colleen; Mead, Elena; Westin, Jason; Kostelecky, Natalie; Mian, Agrima; Herr, Megan M

Risk factors associated with development of coinfection in critically Ill patients with COVID-19

新冠肺炎重症患者发生合并感染的风险因素

Orsini, Erica M; Sacha, Gretchen L; Han, Xiaozhen; Wang, Xiaofeng; Duggal, Abhijit; Rajendram, Prabalini

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

Mavrilimumab治疗重症COVID-19肺炎合并全身性炎症反应(MASH-COVID)患者:一项研究者发起的多中心、双盲、随机、安慰剂对照试验

Cremer, Paul C; Abbate, Antonio; Hudock, Kristin; McWilliams, Carla; Mehta, Jinesh; Chang, Steven Y; Sheng, Calvin C; Van Tassell, Benjamin; Bonaventura, Aldo; Vecchié, Alessandra; Carey, Brenna; Wang, Qiuqing; Wolski, Katherine E; Rajendram, Prabalini; Duggal, Abhijit; Wang, Tisha S; Paolini, John F; Trapnell, Bruce C

Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series

重症患者出现严重免疫检查点抑制剂相关神经毒性:一项多中心病例系列研究

Rajendram, Prabalini; Torbic, Heather; Duggal, Abhijit; Campbell, Jeannee; Hovden, Michael; Dhawan, Vikram; Pastores, Stephen M; Gutierrez, Cristina

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis

托珠单抗治疗2019冠状病毒病相关危重症:一项倾向性匹配分析

Rajendram, Prabalini; Sacha, Gretchen L; Mehkri, Omar; Wang, Xiaofeng; Han, Xiaozhen; Vachharajani, Vidula; Duggal, Abhijit

A High Neutrophil-Lymphocyte Ratio Is Associated With Increased Morbidity and Mortality in Patients With Coronavirus Disease 2019

中性粒细胞与淋巴细胞比例升高与2019冠状病毒病患者的发病率和死亡率增加相关

King, Alexander H; Mehkri, Omar; Rajendram, Prabalini; Wang, Xiaofeng; Vachharajani, Vidula; Duggal, Abhijit

Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation

一项针对 COVID-19 相关心脏损伤和炎症加剧患者的卡那单抗双盲随机概念验证试验

Cremer, Paul C; Sheng, Calvin C; Sahoo, Debasis; Dugar, Siddharth; Prada, Robier Aguillon; Wang, Tom Kai Ming; Hassan, Ossama K Abou; Hernandez-Montfort, Jamie; Wolinsky, David A; Culver, Daniel A; Rajendram, Prabalini; Duggal, Abhijit; Brennan, Danielle M; Wolski, Katherine E; Lincoff, A Michael; Nissen, Steven E; Menon, Venu

Tocilizumab therapy in 5 solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2

托珠单抗治疗 5 例因 SARS-CoV-2 感染而出现早期 ARDS 的实体和复合组织移植受者

Morillas, Jose A; Marco Canosa, Francisco; Srinivas, Pavithra; Asadi, Tannaz; Calabrese, Cassandra; Rajendram, Prabalini; Budev, Marie; Poggio, Emilio D; Narayanan Menon, K V; Gastman, Brian; Koval, Christine